StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Cancidas (caspofungin, legacy) — Worldwide sales by Quarter

Cancidas (caspofungin, legacy) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Cancidas (caspofungin, legacy) — Worldwide sales: $36M in Q4 2022, down 20.0% from a year earlier. That is the lowest of the 28 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2022
36
Period ended Dec 31, 2022
Change on a year earlier
-20.0%
45 in Q4 2021
History
28 quarters
Since Q1 2016
Sources
7
Documents cited below

Where the Q4 2022 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2023-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202236-20.0%Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 202243-23.2%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202242-22.2%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2022Mar 31, 202253-7.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2021Dec 31, 202145-30.8%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q3 2021Sep 30, 202156+12.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202154+25.6%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q1 2021Mar 31, 202157+3.6%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q4 2020Dec 31, 202065+12.1%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2020Sep 30, 202050-19.4%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q2 2020Jun 30, 202043-35.8%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q1 2020Mar 31, 202055-9.8%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q4 2019Dec 31, 201958-15.9%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2019Sep 30, 201962-21.5%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q2 2019Jun 30, 201967-23.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q1 2019Mar 31, 201961-33.0%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗

Breakdown

What makes up cancidas (caspofungin, legacy) — Worldwide sales

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) — Worldwide sales ($M), quarterly Q1 2016–Q4 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas

See every metric in the Merck KPI table. Data updated Oct 26, 2026.